FDA-Approved Drugs with Potent In Vitro Antiviral Activity against Severe Acute Respiratory Syndrome Coronavirus 2.
COVID-19
SARS-CoV-2
antiviral
drug repurposing
virtual screening
Journal
Pharmaceuticals (Basel, Switzerland)
ISSN: 1424-8247
Titre abrégé: Pharmaceuticals (Basel)
Pays: Switzerland
ID NLM: 101238453
Informations de publication
Date de publication:
04 Dec 2020
04 Dec 2020
Historique:
received:
22
10
2020
revised:
30
11
2020
accepted:
01
12
2020
entrez:
9
12
2020
pubmed:
10
12
2020
medline:
10
12
2020
Statut:
epublish
Résumé
(1) Background: Drug repositioning is an unconventional drug discovery approach to explore new therapeutic benefits of existing drugs. Currently, it emerges as a rapid avenue to alleviate the COVID-19 pandemic disease. (2) Methods: Herein, we tested the antiviral activity of anti-microbial and anti-inflammatory Food and Drug Administration (FDA)-approved drugs, commonly prescribed to relieve respiratory symptoms, against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), the viral causative agent of the COVID-19 pandemic. (3) Results: Of these FDA-approved antimicrobial drugs, Azithromycin, Niclosamide, and Nitazoxanide showed a promising ability to hinder the replication of a SARS-CoV-2 isolate, with IC
Identifiants
pubmed: 33291642
pii: ph13120443
doi: 10.3390/ph13120443
pmc: PMC7761982
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : National Research Centre
ID : MP120801
Organisme : Egyptian Academy of Scientific Research & Technology (ASRT), "Ideation Fund" program
ID : 7303
Organisme : NIAID NIH HHS
ID : HHSN272201400006C
Pays : United States
Références
Science. 2020 Mar 13;367(6483):1260-1263
pubmed: 32075877
Lancet Microbe. 2020 May;1(1):e11
pubmed: 32835323
J Virus Erad. 2020 Apr 30;6(2):52-60
pubmed: 32405422
N Engl J Med. 2012 Nov 8;367(19):1814-20
pubmed: 23075143
Drug Discov Today Technol. 2010 Autumn;7(3):e147-202
pubmed: 24103767
Influenza Other Respir Viruses. 2017 Jan;11(1):85-92
pubmed: 27542891
Science. 2020 Apr 24;368(6489):409-412
pubmed: 32198291
Zhongguo Zhong Yao Za Zhi. 1995 Sep;20(9):556-8, 576, inside backcover
pubmed: 8679095
Euro Surveill. 2020 Mar;25(10):
pubmed: 32183930
ACS Infect Dis. 2020 May 8;6(5):909-915
pubmed: 32125140
Antimicrob Agents Chemother. 2002 Sep;46(9):2854-64
pubmed: 12183238
Pathol Biol (Paris). 1995 Jun;43(6):505-11
pubmed: 8539072
Cell Mol Life Sci. 1999 Oct 15;56(3-4):305-12
pubmed: 11212358
J Biol Chem. 2015 Aug 7;290(32):19403-22
pubmed: 26055715
Emerg Microbes Infect. 2020 Dec;9(1):221-236
pubmed: 31987001
BMJ. 2020 Mar 27;368:m1185
pubmed: 32220865
N Engl J Med. 2020 Feb 20;382(8):727-733
pubmed: 31978945
Cell Host Microbe. 2015 Oct 14;18(4):398-401
pubmed: 26468744
Cell Res. 2020 Mar;30(3):269-271
pubmed: 32020029
J Genet Eng Biotechnol. 2020 Jul 28;18(1):35
pubmed: 32725286
Microorganisms. 2020 Jul 02;8(7):
pubmed: 32630780
BMJ. 2020 May 18;369:m1983
pubmed: 32423901
Ecancermedicalscience. 2020 Mar 30;14:1023
pubmed: 32256706
J Hepatol. 2019 Jun;70(6):1222-1261
pubmed: 30926241
J Immunol Methods. 1983 Dec 16;65(1-2):55-63
pubmed: 6606682
Nat Rev Drug Discov. 2019 Jan;18(1):41-58
pubmed: 30310233
Emerg Microbes Infect. 2014 Dec;3(12):e84
pubmed: 26038505
Antimicrob Agents Chemother. 2019 Sep 16;:
pubmed: 31527024
Phytomedicine. 2003;10(6-7):504-10
pubmed: 13678235
Antimicrob Agents Chemother. 1980 May;17(5):865-70
pubmed: 7396473
J Med Chem. 2020 Oct 22;63(20):11397-11419
pubmed: 32511920
Nat Commun. 2017 Apr 10;8:15092
pubmed: 28393837
Cureus. 2020 Sep 17;12(9):e10501
pubmed: 32963923
Ann Rheum Dis. 2020 Apr 22;:
pubmed: 32321720
Nature. 2020 Jun;582(7811):289-293
pubmed: 32272481
Pharmazie. 2015 May;70(5):331-6
pubmed: 26062303
J Med Chem. 2012 Apr 12;55(7):3261-73
pubmed: 22452412
Sci Rep. 2020 Aug 4;10(1):13093
pubmed: 32753646